T3862

Irigenin 可通过特异性和选择性地阻断 Extra Domain A 域的 C-C 环上α9β1和α4β1整合素结合位点，介导其抗转移作用。可通过增强胃癌细胞中促凋亡分子的表达来敏化 TRAIL 诱导的凋亡，具有抗癌作用。

Bcl-xL antagonist 2 是一种有效的选择性 Bcl-xL 拮抗剂，IC50 为 91 nM，Ki 为 65 nM。 Bcl-xL antagonist 2 可诱导癌细胞凋亡，可用于慢性淋巴细胞白血病和非霍奇金淋巴瘤的研究。

Tanimilast (CHF-6001) 是一种新型的高效选择性磷酸二酯酶 4 抑制剂，IC 50值为0.026 ± 0.006 nM。Tanimilast 具有强大的抗炎活性，适用于肺部局部用药。Tanimilast 用于研究阻塞性肺病。

Prexasertib dimesylate (LY2606368 dimesylate) is a highly selective ATP-competitive second-generation inhibitor of checkpoint kinase 1 (CHK1). With a K i of 0.9 nM and an IC 50 of <1 nM, Prexasertib dimesylate effectively inhibits CHK2 (IC 50 = 8 nM) and RSK1 (IC 50 = 9 nM). Its mechanism of action involves inducing double-stranded DNA breakage and replication catastrophe, ultimately leading to apoptosis. Moreover, Prexasertib dimesylate demonstrates potent anti-tumor activity.

SJM-3 is a positive allosteric modulator of various isoforms of the GABAA receptor, specifically binding to the high-affinity benzodiazepine binding site located at the α+/γ- subunit interface.

Ifidancitinib (ATI-50002) 是一种特异性 JAK 激酶 1/3 抑制剂，诱导受 AA 影响的 C3H/HeJ 小鼠的毛发生长。Ifidancitinib可用于研究自身免疫疾病。

Fosifidancitinib 是有效的JAK 激酶 1/3 选择性抑制剂。它在过敏、哮喘和自身免疫性疾病中有研究价值。

GSK143 is a potent orally active and highly selective inhibitor of spleen tyrosine kinase (SYK) with a pIC 50 of 7.5. Furthermore, GSK143 effectively inhibits phosphorylated Erk (pErk) with a pIC 50 value of 7.1. In addition, GSK143 exhibits promising anti-inflammatory properties by reducing inflammation and impeding the recruitment of immune cells in the intestinal muscularis of mice.

Biotin-PEG3-SH 是一种 PROTAC linker，由生物素、PEG和巯基组成，可用于合成 PROTAC 。

Azido-PEG2-propargyl is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Folate-PEG3-alkyne is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.